These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 32192521)

  • 1. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase.
    Mengel D; Liu W; Glynn RJ; Selkoe DJ; Strydom A; Lai F; Rosas HD; Torres A; Patsiogiannis V; Skotko B; Walsh DM
    Alzheimers Res Ther; 2020 Mar; 12(1):27. PubMed ID: 32192521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
    Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A
    Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma NT1-tau and Aβ
    Stern AM; Van Pelt KL; Liu L; Anderson AK; Ostaszewski B; Mapstone M; O'Bryant S; Petersen ME; Christian BT; Handen BL; Selkoe DJ; Schmitt F; Head E;
    Alzheimers Dement; 2023 Dec; 19(12):5755-5764. PubMed ID: 37438872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and predictive power of plasma proteins in Alzheimer's disease: a cross-sectional and longitudinal study in China.
    Li W; Sun L; Yue L; Xiao S
    Sci Rep; 2024 Jul; 14(1):17557. PubMed ID: 39080359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients.
    Shinomoto M; Kasai T; Tatebe H; Kondo M; Ohmichi T; Morimoto M; Chiyonobu T; Terada N; Allsop D; Yokota I; Mizuno T; Tokuda T
    PLoS One; 2019; 14(4):e0211575. PubMed ID: 30951523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
    Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Fagan AM; Henson RL; Li Y; Boerwinkle AH; Xiong C; Bateman RJ; Goate A; Ances BM; Doran E; Christian BT; Lai F; Rosas HD; Schupf N; Krinsky-McHale S; Silverman W; Lee JH; Klunk WE; Handen BL; Allegri RF; Chhatwal JP; Day GS; Graff-Radford NR; Jucker M; Levin J; Martins RN; Masters CL; Mori H; Mummery CJ; Niimi Y; Ringman JM; Salloway S; Schofield PR; Shoji M; Lott IT; ;
    Lancet Neurol; 2021 Aug; 20(8):615-626. PubMed ID: 34302786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome.
    Hamlett ED; Goetzl EJ; Ledreux A; Vasilevko V; Boger HA; LaRosa A; Clark D; Carroll SL; Carmona-Iragui M; Fortea J; Mufson EJ; Sabbagh M; Mohammed AH; Hartley D; Doran E; Lott IT; Granholm AC
    Alzheimers Dement; 2017 May; 13(5):541-549. PubMed ID: 27755974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis.
    Koychev I; Jansen K; Dette A; Shi L; Holling H
    J Alzheimers Dis; 2021; 79(1):177-195. PubMed ID: 33252080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome.
    Tatebe H; Kasai T; Ohmichi T; Kishi Y; Kakeya T; Waragai M; Kondo M; Allsop D; Tokuda T
    Mol Neurodegener; 2017 Sep; 12(1):63. PubMed ID: 28866979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study.
    Dong Y; Hou T; Li Y; Liu R; Cong L; Liu K; Liu C; Han X; Ren Y; Tang S; Winblad B; Blennow K; Wang Y; Du Y; Qiu C
    J Alzheimers Dis; 2023; 96(2):845-858. PubMed ID: 37899059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses.
    Alhajraf F; Ness D; Hye A; Strydom A
    Dev Neurobiol; 2019 Jul; 79(7):684-698. PubMed ID: 31389176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
    Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
    JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease.
    Mengel D; Janelidze S; Glynn RJ; Liu W; Hansson O; Walsh DM
    Ann Neurol; 2020 Nov; 88(5):878-892. PubMed ID: 32829532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome.
    Lleó A; Carmona-Iragui M; Videla L; Fernández S; Benejam B; Pegueroles J; Barroeta I; Altuna M; Valldeneu S; Xiao MF; Xu D; Núñez-Llaves R; Querol-Vilaseca M; Sirisi S; Bejanin A; Iulita MF; Clarimón J; Blesa R; Worley P; Alcolea D; Fortea J; Belbin O
    Alzheimers Res Ther; 2021 Jun; 13(1):119. PubMed ID: 34183050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression.
    Mengel D; Mok TH; Nihat A; Liu W; Rissman RA; Galasko D; Zetterberg H; Mead S; Collinge J; Walsh DM
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals.
    Sun Q; Ni J; Wei M; Long S; Li T; Fan D; Lu T; Shi J; Tian J
    Front Aging Neurosci; 2022; 14():963845. PubMed ID: 36062146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.